Tirzepatide

Tirzepatide, also published as LY3298176, is catalogued here as: GIP and GLP-1 receptor dual agonist. Studied in adults with type 2 diabetes for blood-glucose and body-weight endpoints; GIP and GLP-1 are receptor targets, not independent product benefits. Targets GIP and GLP-1 receptors. Clinical trials in adults with type 2 diabetes measured blood-sugar control and body weight.

Human trial literature: SURPASS-1 randomized 478 adults in a 40-week phase 3 trial; all studied tirzepatide arms improved HbA1c and body-weight endpoints versus placebo. A defined type 2 diabetes population and manufactured trial intervention, not BLOOM material.

Human trial literature: Nausea, diarrhoea and vomiting were the most frequent adverse events, generally mild to moderate and transient. Trial monitoring and findings do not establish safety of a catalogue vial or pen.

When comparing published work, match the exact molecular identity, salt form and strength to the paper. Study findings do not establish outcomes in people. The reconstitution calculator converts vial content and diluent volume into concentration for laboratory preparation.

PEPTIQ lists Tirzepatide as a vial in 30 mg, with pack sizes of 1, 3, 5 and 10. Prices are shown in Canadian dollars, and orders ship from Canada by tracked Canadian service.

A lab report for Tirzepatide is available on request. PEPTIQ does not display a report until it is matched to the exact compound and strength.

Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.